Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D

工程合成免疫细胞具有模块化前哨和 T1D 治疗功能

• 批准号: 10436126
• 负责人: WENDELL A LIM
• 金额: $ 83.08万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10436126
• 关键词: Adhesions; Antigens; Autoimmune Diseases; Beta Cell; CD4 Positive T Lymphocytes; Cell Therapy; Cells; Cytotoxic T-Lymphocytes; Disease; Engineering; Evaluation; Goals; Home; IL2RA gene; Immune; Immunosuppression; Immunotherapeutic agent; In Vitro; Inflammatory; Insulin-Dependent Diabetes Mellitus; Interleukin-10; Islet Cell; Islets of Langerhans; Kidney; Link; Malignant Neoplasms; Modeling; Mus; Output; Patients; Production; Proteins; Reporting; Sentinel; System; Testing; Therapeutic; Tissues; Ursidae Family; autoreactive T cell; capsule; cell type; cellular engineering; cytokine; design-build-test; early onset; flexibility; human pluripotent stem cell; immunoengineering; implantation; in vivo; innovation; insulin dependent diabetes mellitus onset; islet; islet stem cells; new technology; novel; novel strategies; protective factors; receptor; residence; response; sensor; synthetic construct; trafficking

PROJECT SUMMARY Our long-term goal is to engineer therapeutic immune cells that can report on and treat early-stage type 1 diabetes (T1D). Ideally, these cells should home to islets, detect and integrate multi-factor signatures of early- stage disease and, in response, induce localized immunosuppression to block destruction of beta cells. Although this seems like an extraordinarily difficult multi-level challenge, the remarkable progress in engineering immune cells to recognize and kill cancer has generated a broad set of new technologies and approaches that could be brought to bear on cell-based therapies for T1D. Here we propose to repurpose, redirect, and extend cell engineering approaches to construct synthetic immune cells (CD4+ T cells) capable of sensing and treating early-stage autoimmune disorders like T1D. Given the multiple challenges in achieving this goal, we propose to take a modular approach – we have broken up what an ideal anti-T1D cell therapy would have to achieve into three distinct subtasks. Our focus will be on independently engineering and validating cell circuit modules that can achieve these subtasks, which can then be linked together in multiple combinations to develop options for a full therapy. These modular objectives are outlined in our specific aims: Aim 1. ISLET SENSING/TARGETING | Engineer synthetic immune cell sentinels that recognize and establish residence/activity in the pancreas/islets. Sensors of pancreatic/islet specific antigens; islet restricted activation using synNotch receptors; and islet trafficking via synthetic adhesion proteins. Aim 2. AUTOIMMUNE DISEASE SENSING | Engineer synthetic immune cells that sense and report on local immune perturbations associated with T1D onset. Engineer sensors that detect presence of autoreactive T cells and elevated local levels of specific inflammatory cytokines Aim 3. IMMUNO-SUPPRESSIVE OUTPUT: Engineer therapeutic cells that protect islets by inducing local immunosuppressive outputs in response to disease sensing. Engineer output responses encompassing induced local production of suppressive cytokines (IL10, TGFb), inflammatory cytokine sinks (CD25), and other beta-cell protective factors. We will test multiple configurations of linking the disease sensing circuits from Aims 1 and 2 to the suppressive outputs from Aim 3. To develop innovative cell engineering platforms for treating T1D, we propose to focus on human pluripotent stem cell (hPSC)-derived islets as a highly flexible system in which to evaluate the immunoprotective function. hPSC-cells can be readily generated and genetically modified to add convenient model antigens for sensing or killing, allowing for the rapid design-build-test iterative cycles for the circuit modules described above (i.e., making each aim non-dependent on the others). hPSC islets can also be used to assess immunoprotective responses against a variety of islet-targeted cytotoxic T cells, both in vitro and in vivo (implantation in mouse kidney capsule), making this platform ideal for proof-of-principle evaluation and cell circuit optimization.

项目摘要 我们的长期目标是设计治疗性免疫细胞，可以报告和治疗早期1型 糖尿病（T1 D）。理想情况下，这些细胞应该归巢于胰岛，检测并整合早期胰岛细胞的多因素特征。 分期疾病，并作为响应诱导局部免疫抑制以阻断β细胞破坏。虽然 这似乎是一个非常困难的多层次挑战，工程免疫的显着进展， 细胞识别和杀死癌症已经产生了一系列广泛的新技术和方法， 用于T1 D的细胞疗法。在这里，我们建议重新调整、重定向和扩展单元格 构建能够感测和治疗的合成免疫细胞（CD 4 + T细胞）的工程方法 早期自身免疫性疾病比如T1 D鉴于在实现这一目标方面面临的多重挑战，我们建议 采用模块化方法-我们已经将理想的抗T1 D细胞疗法必须实现的目标分解为 三个不同的子任务。我们的重点将是独立设计和验证电池电路模块， 可以实现这些子任务，然后可以将这些子任务以多种组合方式链接在一起，以开发 全套治疗这些模块化目标在我们的具体目标中概述： 目标1.胰岛传感/靶向|设计合成免疫细胞哨兵， 在胰腺/胰岛中建立驻留/活动。胰腺/胰岛特异性抗原传感器;胰岛 使用synNotch受体的限制性激活;以及通过合成粘附蛋白的胰岛运输。 目标2.自身免疫疾病感知|设计合成免疫细胞， 与T1 D发作相关的局部免疫扰动。工程传感器，检测存在的 自身反应性T细胞和局部特异性炎症细胞因子水平升高 目标3.免疫抑制输出：工程治疗细胞，通过诱导局部 免疫抑制输出响应于疾病感测。工程师输出响应，包括 诱导局部产生抑制性细胞因子（IL 10、TGF β）、炎性细胞因子汇（CD 25）和其他 β细胞保护因子。我们将测试连接Aims疾病感知电路的多种配置 目标1和2的抑制性输出与目标3的抑制性输出之间的关系。 为了开发用于治疗T1 D的创新细胞工程平台，我们建议将重点放在人类多能干细胞上。 干细胞（hPSC）衍生的胰岛作为一个高度灵活的系统，其中评估免疫保护功能。 hPSC-细胞可以容易地产生和遗传修饰以添加方便的模型抗原用于感测或免疫原性。 消除，允许上述电路模块的快速设计-构建-测试迭代循环（即， 使每个目标不依赖于其他目标）。hPSC胰岛也可用于评估免疫保护性 在体外和体内（在小鼠中的植入）针对多种胰岛靶向的细胞毒性T细胞的应答 肾胶囊），使该平台成为原理验证评估和电池电路优化的理想选择。